Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study. | Annals of General Psychiatry BioMed Central Primary research Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece A cost effectiveness study Maria Geitona1 Hara Kousoulakou2 Markos Ollandezos3 Kostas Athanasakis3 Sotiria Papanicolaou 4 and Ioannis Kyriopoulos3 Open Access Address Department of Economics University of Thessaly Magnissias 96 Dionyssos 14576 Greece institute for Economic and Industrial Research Tsami Karatasi 11 117 42 Athens Greece 3Department of Health Economics National School of Public Health Aleksandra s Avenue 196 11521 Athens Greece and 4Janssen-Cilag Pharmaceutical SACI Eirinis Avenue 56 15121 Pefki Athens Greece Email Maria Geitona - geitona@econ.uth.gr Hara Kousoulakou - kousoul@iobe.gr Markos Ollandezos - markolan@gmail.com Kostas Athanasakis - k.athanasakis@gmail.com Sotiria Papanicolaou - spapanic@jacgr.jnj.com loannis Kyriopoulos - nsph-kyr@ath.forthnet.gr Corresponding author Published 28 August 2008 Received 4 February 2008 Annals of General Psychiatry 2008 7 16 doi 10.1186 1744-859X-7-16 Accepted 28 August 2008 This article is available from http www.annals-general-psychiatry.cOm content 7 1 16 2008 Geitona et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background To compare the costs and effects of paliperidone extended release ER a new pharmaceutical treatment for the management of schizophrenia with the most frequently prescribed oral treatments in Greece namely risperidone olanzapine quetiapine aripiprazole and ziprasidone over a 1year time period. Methods A decision tree was developed and tailored to the specific circumstances of the Greek healthcare system. Therapeutic effectiveness